Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02736435
Other study ID # RP-317-07302014
Secondary ID
Status Withdrawn
Phase Phase 3
First received March 18, 2016
Last updated February 2, 2018
Start date January 18, 2018
Est. completion date January 18, 2018

Study information

Verified date April 2017
Source Thunder Bay Regional Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the effectiveness of MR-HIFU for the treatment of uterine fibroids in Northwestern Ontario, which is a rural and remote setting.


Description:

Uterine fibroids are benign smooth muscle tumours of the muscular wall of the uterus that affect 40 per cent of women. While the majority of fibroids are asymptomatic, fibroids may cause menorrhagia, bulk symptoms (i.e. ureteric obstruction, urinary frequency and urgency, bowel dysfunction), pain and in certain instances infertility.

Magnetic resonance image-guided high-intensity focused ultrasound (MR-HIFU) treatment of fibroids is an established method for symptom alleviation with over 3000 women receiving treatment worldwide. MR-HIFU is a non-invasive, non-surgical procedure that uses ultrasound energy to thermally ablate the fibroid leading to a reduction in bleeding and in the size of uterine fibroids over time. MR-HIFU it is not currently being used for the treatment of symptomatic fibroids in Canada.

The Thunder Bay Regional Research Institute has one of the first clinically available MR-HIFU equipment in Canada. In order to bring this technology into clinical practice, a knowledge translation study is needed to demonstrate that MR-HIFU can treat symptomatic uterine fibroids as successfully in Northwestern Ontario compared to urban centres where all of the clinical trials have been conducted. The ability to screen and follow up women treated with MR-HIFU with ultrasound rather than MRI would allow participants to receive follow up in regional centres in Northwestern Ontario and it would be more cost effective from a health system perspective. In addition, more research is needed to broaden the scope of treatment to include fibroids greater than 8 cm such that more women could benefit from this non-surgical fibroid management option.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 18, 2018
Est. primary completion date January 18, 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Women aged 18 to 50 years

- Weight <140kg

- Pre or perimenopausal

- Uterine size <24 weeks

- Cervical screen by Pap test: Normal, Low Grade Squamous Intraepithelial Lesion, or Atypical Squamous Cells of Undetermined Significance as per Cancer Care Ontario guidelines

- Transformed symptom severity score =40

- Willing to attend all study visits

- Willing to complete evaluation forms

- Willing and able to use reliable contraception;

MR-HIFU Criteria Trial Arm 1:

- Minimum of 50% of fibroid volume accessible for treatment

- Dominant fibroid =8 cm

- Uterine volume <900 cc

- Total fibroid treatment volume <250 cc

- No more than 5 fibroids planned for ablation

- Completely non-enhancing fibroids should not be treated

MR-HIFU Criteria Trial Arm 2:

- Minimum of 50% of fibroid volume accessible for treatment

- Dominant fibroid >8 cm or uterine volume >900 cc

- Total fibroid treatment volume <250 cc

- No more than 5 fibroids planned for ablation

- Completely non-enhancing fibroids should not be treated

Exclusion Criteria:

- Other pelvic disease (endometriosis, ovarian tumor, acute pelvic disease, other mass)

- Significant systemic disease even if well controlled

- Positive pregnancy test

- Abnormal uterine bleeding (participant can be included if an endometrial biopsy confirms no hyperplasia or malignancy in the past 6 months)

- Extensive scarring along anterior abdominal wall (>50% of area)

- Surgical clips or scar tissue in the path of the MR-HIFU beam

- MRI contraindicated according to standard operating procedure

- MRI contrast contraindicated (including renal insufficiency)

- Calcifications around or throughout uterine tissues

- Fibroids not quantifiable on MRI

- Highly perfused or brighter than myometrium in T2-weighted MRI fibroids (Type 3 fibroids).

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Magnetic Resonance Guided High Intensity Focused Ultrasound
Direct treatment of uterine fibroids with MR-HIFU
Drug:
leuprolide acetate for depot suspension
Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU

Locations

Country Name City State
Canada Thunder Bay Regional Health Sciences Centre Thunder Bay Ontario

Sponsors (1)

Lead Sponsor Collaborator
Thunder Bay Regional Research Institute

Country where clinical trial is conducted

Canada, 

References & Publications (6)

Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991 May;77(5):720-5. — View Citation

Gizzo S, Saccardi C, Patrelli TS, Ancona E, Noventa M, Fagherazzi S, Mozzanega B, D'Antona D, Nardelli GB. Magnetic resonance-guided focused ultrasound myomectomy: safety, efficacy, subsequent fertility and quality-of-life improvements, a systematic review. Reprod Sci. 2014 Apr;21(4):465-76. doi: 10.1177/1933719113497289. Epub 2013 Jul 18. Review. — View Citation

Quinn SD, Vedelago J, Gedroyc W, Regan L. Safety and five-year re-intervention following magnetic resonance-guided focused ultrasound (MRgFUS) for uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2014 Nov;182:247-51. doi: 10.1016/j.ejogrb.2014.09.039. Epub 2014 Oct 6. — View Citation

Smart OC, Hindley JT, Regan L, Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance-guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol. 2006 Jul;108(1):49-54. — View Citation

Stewart EA, Gostout B, Rabinovici J, Kim HS, Regan L, Tempany CM. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol. 2007 Aug;110(2 Pt 1):279-87. — View Citation

Thiburce AC, Frulio N, Hocquelet A, Maire F, Salut C, Balageas P, Bouzgarrou M, Hocké C, Trillaud H. Magnetic resonance-guided high-intensity focused ultrasound for uterine fibroids: Mid-term outcomes of 36 patients treated with the Sonalleve system. Int J Hyperthermia. 2015;31(7):764-70. doi: 10.3109/02656736.2015.1063169. Epub 2015 Sep 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Return to activity within 72 hours of treatment 72 hours
Other Change in hemoglobin level Assessing change from baseline value 3, 6, and 12 months
Primary Change in uterine fibroid symptom severity scale Assessing change from baseline value 3, 6, and 12 months
Secondary Change in short form McGill pain questionnaire Assessing change from baseline value 24h, 72h, 6week, 3, 6, and 12 month
Secondary Change in pictorial blood loss assessment chart Assessing change from baseline value 3, 6, and 12 months
Secondary Change in uterine fibroid symptom and health-related quality of life questionnaire Assessing change from baseline value 12 months
Secondary Participant use of alternative therapies for treatment of fibroids Questionnaire to assess if participants are selecting to use alternative treatments for relief of symptoms of uterine fibroids. 6 weeks, 3, 6, and 12 months
Secondary MR Imaging to assess change in fibroid volume. Assessing change from baseline value 3, 6, and 12 months
Secondary MR Imaging to assess change in perfusion. Assessing change from baseline value 3, 6, and 12 months
Secondary Ultrasound imaging to assess change in fibroid volume. Assessing change from baseline value 3, 6, and 12 months
Secondary Ultrasound imaging to assess change in fibroid perfusion. Assessing change from baseline value 3, 6, and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04519593 - ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma N/A
Not yet recruiting NCT03219385 - Directed Ablation of Uterine Fibroids Using a Noninvasive Approach N/A
Completed NCT01338831 - Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer Phase 1
Completed NCT01468402 - Predictive Factors of Pelvic Magnetic Resonance in the Response of Arterial Embolization of Uterine Leiomyoma N/A
Completed NCT03847077 - Trial of a Patient Education Tool For Leiomyoma N/A
Completed NCT00365989 - MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Phase 3
Completed NCT03751124 - Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids Phase 3
Recruiting NCT02495311 - The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms
Completed NCT00332033 - Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids) Phase 2
Completed NCT04874246 - Comparison of Concentration of Vasopressin During Robot-assisted Laparoscopic Myomectomy N/A
Not yet recruiting NCT04282863 - Comparison Between Robotic (RM) and Laparoscopic Myomectomy (LM) N/A
Recruiting NCT06115408 - Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma Phase 2/Phase 3
Completed NCT02059954 - Vaginal vs. Laparoscopic Hysterectomy N/A
Completed NCT02049242 - Uterine Tourniquet at Open Myomectomy N/A
Terminated NCT01738724 - Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Phase 4
Terminated NCT01280045 - Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy N/A
Completed NCT04819633 - Evaluating Serum Sestrin in Leiomyoma Patients
Completed NCT00341848 - Postpartum Uterine Regression
Completed NCT01715597 - Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma Phase 3
Completed NCT03328260 - High Intensity Focused Ultrasound in Uterine Myoma N/A